STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.

Dayson MoreiraTomasz AdamusXingli ZhaoYu-Lin SuZhuoran ZhangSeok Voon WhitePiotr SwiderskiXin LuRonald A DePinhoSumanta K PalMarcin Kortylewski

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

The bifunctional, immunostimulatory, and tolerance-breaking design of CpG-STAT3ASO offers a blueprint for the development of effective and safer oligonucleotide strategies for treatment of immunologically "cold" human cancers.

Keyphrases

dna methylation
prostate cancer
cell proliferation
endothelial cells
induced pluripotent stem cells
gene expression
young adults
replacement therapy
metal organic framework